Diagnostic open laparoscopy in the management of advanced ovarian cancer

Gynecologic Oncology

Volumn 100, Issue 3, 2006, Pages 455-461

  Angioli, Roberto ^b   Palaia, Innocenza ^a   Zullo, Marzio Angelo ^b   Muzii, Ludovico ^b   Manci, Natalina ^a   Calcagno, Marco ^a   Panici, Pierluigi Benedetti ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Advanced ovarian cancer; Neoadjuvant chemotherapy; Open laparoscopy

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; GYNECOLOGIC SURGERY; HUMAN; LAPAROSCOPY; MAJOR CLINICAL STUDY; OVARY CANCER; PERIOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VALIDATION STUDY;

ADULT; AGED; FEMALE; HUMANS; HYSTERECTOMY; LAPAROSCOPY; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; OVARIECTOMY;

EID: 32644489100     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.060     Document Type: Article

References (33)

1. C.T. Griffith Surgical resection of tumor bulk in the primary treatment of ovarian cancer J. Natl. Cancer Inst. Monogr. 42 1975 101 104
2. N.F. Hacker, J.S. Berek, and L.D. Lagasse Primary cytoreductive surgery for epithelial ovarian cancer Obstet. Gynecol. 61 1983 413 420
3. W. Hoskins, W. McGuire, and M. Brady The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am. J. Obstet. Gynecol. 170 1994 974 979
4. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Monz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during platinum era: a meta-analysis J. Clin. Oncol. 20 2002 1248 1259
5. J. Huober, A. Meyer, U. Wagner, and D. Wallwiener The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer J. Cancer Res. Clin. Oncol. 128 2002 153 160
6. S.M. Eisenkop, R.L. Friedman, and H.J. Wang Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study Gynecol. Oncol. 69 1998 103 108
7. W. Kuhn, G. Florack, J. Roder, SB. Chmalfeldt, L. Pache, and M. Rust The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV Int. J. Oncol. 13 1998 57 63
8. S.S. Chen, and R. Bochner Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma Gynecol. Oncol. 20 1985 190 195
9. P. Venesmaa, and O. Ylikorkala Morbidity and mortality associated with primary and repeat operations for ovarian cancer Obstet. Gynecol. 79 1992 168 172
10. S. Pecorelli, F. Odicino, and G. Favalli Interval debulking surgery in advanced epithelial ovarian cancer Best Pract. Res. Clin. Obstet. Gynecol. 16 2002 573 583
11. F. Fanfani, G. Ferrandina, G. Corrado, A. Fagotti, H. Zakut, and S. Mancuso Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIC ovarian cancer patients Oncology 65 2003 316 322
12. W. Kuhn, S. Rutke, K. Spathe, B. Schmalfeldt, G. Florack, and B. Hundelshauen Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma Cancer 92 2001 2581 2591
13. I. Vergote, I. De Wever, W. Tjalma, M. Van Gramberen, J. Decloedt, and P. van Dam Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol. Oncol. 71 1998 431 436
14. C. Redman, J. Warwick, D. Luesley, R. Varma, F. Lawton, and G. Blackledge Intervention debulking surgery in advanced epithelial ovarian cancer Br. J. Obstet. Gynecol. 101 1994 142 146
15. P. Schwartz Neoadjuvant chemotherapy for the management of ovarian cancer Best Pract. Res. Clin. Obstet. Gynecol. 16 2002 585 596
16. I. Vergote, I. De Wever, W. Tjalma, M. van Gramberen, J. Decloedt, and P. van Dam Interval debulking surgery: an alternative for primary surgical debulking? Sem. Surg. Oncol. 19 2000 49 53
17. P. Morice, G. Dubernard, A. Rey, D. Atallah, P. Pautier, and C. Pomel Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer J. Am. Coll. Surg. 197 2003 955 963
18. M.E.L. van der Burg, M. van Lent, M. Buyse, A. Kobierska, N. Colombo, and G. Favalli The effect of interval debulking surgery after induction chemotherapy on the prognosis in the advanced epithelial ovarian cancer N. Engl. J. Med. 332 1995 629 634
19. M.E.L. van der Burg After 6 years follow-up intervention debulking surgery remains an independent prognostic factor for survival in advanced epithelial ovarian cancer: an EORTC-GCCG study Int. J. Gynecol. Cancer 7 1997
20. P.G. Rose, S. Nerenstone, M. Brady, D. Clarke-Pearson, G. Olt, and S.C. Rubin A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study ASCO Proc. 21 2002 802 [abstract No 802]
21. Y. Ansquer, E. Leblanc, K. Clough, P. Morice, J. Dauplet, and P. Mathevet Neoadjuvant chemotherapy for unresectable ovarian carcinoma Cancer 91 2001 2329 2334
22. B.E. Nelson, A.T. Rosenfield, and P.E. Schwartz Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma J. Clin. Oncol. 11 1993 166 172
23. S. Dowdy, S. Mullany, K. Brandt, B. Huppert, and W. Cliby The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma Cancer 101 2004 346 352
24. R. Bristow, L. Duska, and N. Lambrou A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography Cancer 89 2000 1532 1540
25. J. Meyer, A. Kennedy, R. Friedman, A. Ayoub, and R. Zepp Ovarian carcinoma: value of CT in preediting success of debulking surgery AJR Am. J. Roentgenol. 165 1995 875 878
26. E. Brockbank, T. Ind, D. Barton, J. Shepherd, M. Gore, and R. Hern Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer Int. J. Gynecol. Cancer 14 2004 42 50
27. D. Chi, E. Venkatraman, V. Masson, and W. Hoskins The ability of preoperative serum Ca125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma Gynecol. Oncol. 77 2000 227 231
28. U. Saygili, S. Guclu, T. Uslu, O. Erten, N. Demir, and A. Onvural Can serum Ca125 levels predict the optimal primary cytoreduction in patients with advanced epithelial ovarian carcinoma? Gynecol. Oncol. 86 2002 57 61
29. S. Memarzadeh, S. Lee, J. Berek, and R. Farias-Eisner Ca125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer Obstet. Gynecol. 100 2002 59 64
30. A. Berchuck, E. Iversen, J. Lancaster, H. Dressman, M. West, and J. Nevins Prediction of optimal versus suboptimal cytoreduction of advanced stage serous ovarian cancer with the use of microarrays Am. J. Obstet. Gynecol. 190 2004 910 925
31. A. Fagotti, F. Fanfani, M. Ludovisi, R. Lo Voi, G. Bifulco, and A. Testa Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study Gynecol. Oncol. 96 2005 729 735
32. I. Tannock Cell kinetics and chemotherapy: a critical review Cancer Treat. Rep. 62 1979 1117 1133
33. J.H. Golde, and A.J. Coldman A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate Cancer Treat. Rep. 63 1979 1727 1733